하지불안증후군에서 Ferric Carboxymaltose 정맥 주사 치료반응과 관련된 임상 요인
Clinical Factors Related to the Response of IV Ferric Carboxymaltose Treatment in Patients with Restless Legs Syndrome
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: Significant benefit of intravenous ferric carboxymaltose (FCM) for restless legs syndrome (RLS) has been demonstrated. However, clinical indicators to expect treatment response of RLS are not clarified. The aim of this study is to find out determinant factors to predict treatment outcome of FCM. Methods: We enrolled consecutive 108 patients with RLS who visited sleep clinic and received FCM from April 2016 to November 2017. Obtained data were detailed history including international restless legs scale (IRLS) and questionnaires, comorbid diseases, medication. Complete blood cell count, serum iron, ferritin, and total iron-binding capacity were sampled before and after treatment. Treatment response was assessed about four weeks after FCM administration. Patients with more than 40% decrease on IRLS were classified into the responders. Results: 99 patients (mean 54.5 y and 79 females) were included. 58 patients (58.6%) were classified to be responders. There were substantial differences in post-treatment IRLS and symptom reduction rate between responders (7.4±6.4, 77.5±18.6%) and non-responders (29.7±8.7, 7.4±10.3%). No significant differences were found in demographics, baseline IRLS, sleep, and mood status between two groups. Serum ferritin and transferrin saturation was significantly lower in responders (37.6 ng/mL, 25.0%) than non-responders (55.1 ng/mL, p=0.014 and 36.5%, p=0.001). Patients with a history of gastrectomy (n=8) showed an excellent response to FCM (83.8% of symptom reduction). Comorbid lumbosacral radiculopathy had lower response rate (29.4%). Conclusions: Peripheral iron compromised state and gastrectomy history may indicate good response to intravenous FCM in patients with RLS. Patients with lumbosacral radiculopathy tend to be poor responders to intravenous FCM.
Abstract
Objectives: Significant benefit of intravenous ferric carboxymaltose (FCM) for restless legs syndrome (RLS) has been demonstrated. However, clinical indicators to expect treatment response of RLS are not clarified. The aim of this study is to find out determinant factors to predict treatment outcome of FCM. Methods: We enrolled consecutive 108 patients with RLS who visited sleep clinic and received FCM from April 2016 to November 2017. Obtained data were detailed history including international restless legs scale (IRLS) and questionnaires, comorbid diseases, medication. Complete blood cell count, serum iron, ferritin, and total iron-binding capacity were sampled before and after treatment. Treatment response was assessed about four weeks after FCM administration. Patients with more than 40% decrease on IRLS were classified into the responders. Results: 99 patients (mean 54.5 y and 79 females) were included. 58 patients (58.6%) were classified to be responders. There were substantial differences in post-treatment IRLS and symptom reduction rate between responders (7.4±6.4, 77.5±18.6%) and non-responders (29.7±8.7, 7.4±10.3%). No significant differences were found in demographics, baseline IRLS, sleep, and mood status between two groups. Serum ferritin and transferrin saturation was significantly lower in responders (37.6 ng/mL, 25.0%) than non-responders (55.1 ng/mL, p=0.014 and 36.5%, p=0.001). Patients with a history of gastrectomy (n=8) showed an excellent response to FCM (83.8% of symptom reduction). Comorbid lumbosacral radiculopathy had lower response rate (29.4%). Conclusions: Peripheral iron compromised state and gastrectomy history may indicate good response to intravenous FCM in patients with RLS. Patients with lumbosacral radiculopathy tend to be poor responders to intravenous FCM.
참고문헌 (19)
- Allen RP, "Restless legs syndrome: a review of clinical and pathophysiologic features", J Clin Neurophysiol, 18, pp.128~147 (2001)[DOI]
- Nordlander NB, "Therapy in restless legs", Acta Med Scand, 145, pp.453~457 (1953)
- Davis BJ, "A randomized, double-blind placebo-controlled trial of iron in restless legs syndrome", Eur Neurol, 43, pp.70~75 (2000)[DOI]
- Wang J, "Efficacy of oral iron in patients with restless legs syndrome and a low-normal ferritin: a randomized, double-blind, placebo-controlled study", Sleep Med, 10, pp.973~975 (2009)[DOI]
- Earley CJ, "The treatment of restless legs syndrome with intravenous iron dextran", Sleep Med, 5, pp.231~235 (2004)[DOI]
- Grote L, "A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome", Mov Disord, 24, pp.1445~1452 (2009)[DOI]
- Earley CJ, "A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome", Sleep Med, 10, pp.206~211 (2009)[DOI]
- Allen RP, "Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial", Sleep Med, 12, pp.906~913 (2011)[DOI]
- Cho YW, "Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome", Sleep Med, 25, pp.16~23 (2016)[DOI]
- Friedrisch JR, "Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia", Rev Bras Hematol Hemoter, 37, pp.400~405 (2015)[DOI]
- Trenkwalder C, "Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: a randomized trial", Mov Disord, 32, pp.1478~1482 (2017)[DOI]
- Allen RP, "Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome", Willis-Ekbom disease in adults and children: an IRLSSG task force report, 2018, pp.41, 27~44
- Hornyak M, "Investigating the response to intravenous iron in restless legs syndrome: an observational study", Sleep Med, 13, pp.732~735 (2012)[DOI]
- Walters AS, "Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group", Mov Disord, 10, pp.634~642 (1995)[DOI]
- Trenkwalder C, "Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial", Lancet Neurol, 7, pp.595~604 (2008)[DOI]
- Earley CJ, "Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome", Neurology, 54, pp.1698~1700 (2000)[DOI]
- Mizuno S, "CSF iron, ferritin and transferrin levels in restless legs syndrome", J Sleep Res, 14, pp.43~47 (2005)[DOI]
- Lim CH, "Anemia after gastrectomy for early gastric cancer: long-term follow-up observational study", World J Gastroenterol, 18, pp.6114~6119 (2012)[DOI]
- Kocabicak E, "Restless leg syndrome and sleep quality in lumbar radiculopathy patients", Behav Neurol, 2014, pp.245358~ (2014)